PEspeaks

Apr 04, 2018
FDA is moving slowly in liberalizing off-label communications amid outrage over opioid promotion. Jill Wechsler reports.
Mar 31, 2018
In terms of important clinical benefits and outcomes, modern biotech products have rarely shown the advantages of older generations of drugs, writes Bagrat Lalayan.
Mar 21, 2018
Looking back at the agenda of a 1985 EFPIA conference, Reflector sees that, three decades on, the European drug industry is still seeking a pill for its own ills.
Mar 07, 2018
Pharmaceutical Executive
Tackling some of the unintended consequences associated with value-based contracting in pharma and efforts to advance toward sustainable outcomes-based engagement.
Mar 07, 2018
Pharmaceutical Executive
The public and policymakers seek more transparency in pricing and product development.
Feb 20, 2018
In the coming weeks, the EU will decide if the degree of protection offered to drug firms by research incentives such as the SPC are really in the interests of patients and society. Reflector reports.
Feb 16, 2018
Rather than looking at what their peers are doing in digital health, pharma companies need to anticipate new challengers in the healthcare industry, writes Kal Patel.
Feb 15, 2018
Pharmaceutical Executive
This blog discusses the benefits of the pharma industry adopting the idea that media is data.
Feb 06, 2018
Pharmaceutical Executive
Drawing parallels from the world of football coaching in evaluating and grooming future C-suite pharma leaders—call it the quest to see "what right looks like?"
Feb 06, 2018
Pharmaceutical Executive
Julian Upton assembles a few rare slivers of positivity on UK pharma's future.
native1_300x100
lorem ipsum